CJMB CALLAN JMB INC. Insider Trading

Chief Medical Officer David J Croyle bought 10,195 shares of CJMB at $1.75 on 2026-03-20; prior CJMB buys showed +10.9% and +22.9% 90-day gains.

David J Croyle, Chief Medical Officer, purchased 10,195 shares at $1.75, expanding his holdings to 800,000 shares. This marks his third open-market buy at CJMB in roughly one year; his prior two purchases at this ticker generated 90-day returns of +10.9% and +22.9%, both positive outcomes. His cross-ticker track record shows a 100% 90-day win rate across 3 prior buys with an average 90-day return of +16.9%. However, the broader context raises caution: the company reported quarterly net income of $-2.7M against revenue of $1.4M, with annual revenue contracting 50.3% year-over-year and a market cap of only $8.4M. The stock currently trades at $1.81, down 68.4% from its 52-week high of $5.72. While the insider's prior timing at this ticker has been favorable, the fundamental deterioration and severe valuation decline warrant scrutiny of whether this purchase reflects a different risk calculus than his previous successful accumulations.

CMO Croyle buys 14,805 shares of CJMB at $1.76 as stock trades -69.4% from 52-week high; company unprofitable with -50.3% revenue decline.

David J Croyle, Chief Medical Officer, purchased 14,805 shares at $1.76 on 2026-03-06, expanding his holdings to 789,805 shares and representing a +1.9% increase in position size. This buy occurs against a challenging backdrop: the stock trades at $1.76, which is -69.4% from its 52-week high of $5.76, and the company reported a net income of $-2.7M against quarterly revenue of $1.4M with annual revenue growth of -50.3%. Notably, Croyle's two prior purchases at CJMB in 2025 exhibited positive 90-day returns of +7.8% and +10.9%, establishing a pattern of well-timed entry points at this ticker. His cross-ticker track record shows 2 prior buys with a 100.00% 90-day win rate and average 90d return of +16.9%, though this broader context must be weighed against the company's deteriorating operational fundamentals and significant stock price decline from recent highs.

Director Dial Gerald buys 2,000 shares ($2.4K) at $1.20–$1.22 amid 81.3% decline from 52-week high; company unprofitable with 50.3% revenue drop.

Director Dial Gerald acquired 2,000 shares in 2 separate purchases totaling $2,409.22 at a blended average price of $1.20, establishing an initial position in CALLAN JMB INC. The acquisition occurs in a context of severe deterioration: the stock is down 81.3% from its 52-week high of $6.32, down 74.4% over the past 90 days, and down 24.8% over the past 30 days. Fundamentally, the company reported a net loss of $-2,731,341.00 with annual revenue declining 50.3%, and is trading at a market cap of $5.5M. The purchase price of $1.20–$1.22 is slightly above the current price of $1.18, indicating the transaction predates any further near-term decline. This represents a director's first measurable stake, but occurs against a backdrop of financial distress and equity destruction that requires scrutiny into the transaction's motive and the company's trajectory.

CEO Wayne D Williams buys 5,000 CJMB shares at $1.73 amid -77.1% decline from 52-week high; company unprofitable with -50.3% revenue decline

Williams purchased 5,000 shares at $1.73 on 2025-12-16, increasing his holdings to 84,355 shares (+6.3%), during a period of severe stock underperformance: the current price of $1.45 is -77.1% below the 52-week high and down -70.9% over 90 days. This is the CEO's 5th consecutive buy of CJMB in a 6-day window (2025-12-10 through 2025-12-16), with prior outcomes not yet measurable at the 30- and 90-day horizons. The fundamentals present substantial headwinds: the company posted quarterly revenue of $1.4M against a net loss of $-2.7M, and full-year revenue contracted -50.3% year-over-year while the company remained unprofitable. Although Williams's cross-ticker track record shows an 8-trade average 90-day return of +22.9% with a 100% win rate, those results cannot be attributed to CJMB performance, where no prior trade outcomes are yet measurable. The rapid consecutive accumulation at a collapsed valuation warrants monitoring to assess whether this reflects a recovery thesis or reflects execution of a pre-planned hedge given deteriorating operational results.

CEO Williams bought 15,798 shares at blended $1.72 across 3 days; stock down -72.9% from 52-week high amid -50.3% revenue decline and -$2.7M net loss.

Williams Wayne D, CEO/Chairman/President, made 3 separate purchases totaling 15,798 shares for $27,108.48 at prices ranging from $1.70 to $1.79 on 2025-12-11, 2025-12-12, and 2025-12-15, increasing his holdings by 24.9%. The timing of these purchases follows a 52-week decline of -72.9% from the $6.32 high and a 30-day drop of -52.6%, placing them near recent lows. Separately, the company's most recent quarter shows revenue of $1,446,917.00 with net income of -$2,731,341.00, and annual revenue growth was -50.3%; the company remains unprofitable on a full-year basis. His cross-ticker track record shows 5 prior buys with a 100% 90-day win rate and average 90-day return of +22.9%, though his same-ticker history at CJMB encompasses only earlier trades from 2025-02-05 with measurable gains, while the current filing's timing patterns remain unmeasured. The confluence of steep stock decline, negative operating fundamentals, and substantial insider accumulation near recent lows merits investor scrutiny of the company's near-term operational trajectory.

CEO Wayne D Williams buys 44,545 shares at $1.65 in 2 transactions; holdings surge 185.6% amid 71.8% slide from 52-week high

Wayne D Williams, CEO and Chairman of CALLAN JMB INC., purchased 44,545 shares across 2 open-market transactions on 2025-12-10 and 2025-12-11 at a blended average price of $1.65, expanding his holdings from 24,000 to 68,545 shares (a 185.6% increase). This aggressive accumulation follows a severe drawdown: the stock trades at $1.78, down 71.8% from its 52-week high of $6.32 and down 53.0% over the prior 30 days. The company faces significant headwinds—annual revenue declined 50.3% year-over-year to $1,446,917.00, net income is negative at $-2,731,341.00, and the firm is unprofitable. Across his cross-ticker track record, Williams has achieved a 100% 90-day win rate on 5 prior buys with an average 90-day return of +22.9%; his same-ticker history at CJMB shows 3 prior buys (all on 2025-02-05) that were well-timed at the 90-day mark with +22.9% returns. The scale of this purchase and the severity of the current valuation decline relative to his demonstrated prior timing accuracy merit close investor attention to the fundamental triggers behind his conviction.

Director Duke Liberty Smith purchases 1,512 shares ($2,334.24) at $1.54 avg price amid -65.8% 90-day decline and -$2.7M net income loss.

Duke Liberty Smith, a director at CALLAN JMB INC., initiated a new position with two separate purchases totaling 1,512 shares for $2,334.24 on consecutive days (900 shares at $1.56 on 2025-12-08 and 612 shares at $1.52 on 2025-12-09). The transaction occurs against a backdrop of significant stock weakness: the share price has declined 65.8% over the trailing 90 days and trades at $1.78 compared to a 52-week high of $6.32. The company faces structural challenges with negative full-year net income of $-2.7M, revenue declining 50.3% year-over-year, and quarterly revenue of only $1.4M. The timing and modest scale of this open-market purchase in a deep value context warrants scrutiny of whether this represents meaningful director conviction or merely a routine portfolio action by a new shareholder position holder.

CMO Croyle David J bought 25,000 shares at $4.50 on 2025-03-27; stock now $3.92, down 19.7% in 30 days.

Croyle David J, Chief Medical Officer, purchased 25,000 shares at $4.50 on 2025-03-27, bringing his holdings to 775,000 shares. The transaction occurred against a backdrop of deteriorating company fundamentals: CALLAN JMB is trading 38.0% below its 52-week high of $6.32, has experienced annual revenue decline of -50.3%, and reported negative full-year net income over its most recent fiscal year. Since the purchase, the stock has declined 19.7% over 30 days, now trading at $3.92. The insider's cross-ticker track record shows only 1 prior buy with an average 30-day return of +8.8%, while his single prior transaction at CJMB (a buy on 2025-02-05) has achieved a 30-day return of +8.8%, though 90-day outcomes remain unmeasurable at this ticker. The purchase represents a 3.3% increase in holdings but occurs within a narrow track record and during a period of acute financial stress at the company.

Chief Medical Officer Croyle buys 24,375 shares of CJMB at $4.00 for $97,500.00

Croyle David J, Chief Medical Officer of Callan JMB Inc., purchased 24,375 shares at $4.00, establishing an initial position with zero prior holdings in this recently-listed company. The stock currently trades at $5.30, representing a 32.5% gain from the purchase price. This acquisition by a C-suite executive in a company where he holds no measurable prior ownership suggests initial capital commitment, though the modest position size and early-stage trading history (27 trading days post-listing) provide limited context for assessing the significance of this stake relative to his overall financial interests or broader insider activity patterns.

CEO Wayne Williams buys 63,125 shares at $4.00 for $252,500 at newly-listed CJMB, clearing short position

Wayne D Williams, CEO and President, executed 3 separate purchases totaling 63,125 shares for $252,500.00 at $4.00 per share on 2025-02-05. The transaction is noteworthy because it shifts his holdings from -38,125 shares (a short position or prior obligation) to a positive 25,000 share position post-transaction. This represents elimination of a net short and establishment of a material long stake by the company's top executive in a recently-listed company (27 trading days old at time of analysis). The timing during early public trading in a newly-listed security, combined with the magnitude of capital deployed and the complete position reversal, warrants investor attention to management's confidence in the listing stage of the business.